Patents Assigned to Mitsubishi Pharma Corporation
  • Medicament for prevention and/or therapy of arterial wall disorder
    Patent number: 7312239
    Abstract: An object of the present invention is to provide a medicament and method which is useful for prevention and/or therapy of arterial wall injury.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: December 25, 2007
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Takayuki Tanaka, Tatsuhiko Mori
  • Production Method of Phenylethanolamine Compound, and Its Intermediate
    Publication number: 20070287864
    Abstract: A novel production method for a phenylethanolamine compound of the following general formula (III): (wherein R1 represents a hydrogen atom or a halogen atom; R2 represents an alkyl group optionally substituted with an alkoxycarbonyl group); and a novel production intermediate for it.
    Type: Application
    Filed: October 19, 2005
    Publication date: December 13, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Nobuyuki Yasuda, Tsuyoshi Kajita
  • Pharmaceutical Formulations Comprising Paraoxonase
    Publication number: 20070280916
    Abstract: The present invention provides a pharmaceutical formulation comprising paraoxonase (PON), a purification and stabilization method of PON, and an agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction containing PON as an active ingredient.
    Type: Application
    Filed: February 4, 2005
    Publication date: December 6, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Naomi Asahara, Motonori Hashimoto, Satoshi Yuki
  • Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease
    Publication number: 20070270409
    Abstract: A medicament for preventing and/or treating an ischemic cardiovascular disease, which contains as an active ingredient a compound of an aminobenzenesulfonic acid derivative represented by the following general formula (I): (refer to the description for the symbols in the formula) or a salt thereof, or a hydrate or solvate thereof, characterized in that it is administered to a patient undergoing percutaneous coronary intervention.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 22, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventor: Jun Tatsuno
  • Quinazoline Derivative and Process for Producing the Same
    Publication number: 20070270589
    Abstract: Object: To offer novel quinazoline derivatives, which are useful as intermediates in the production of agents for the treatment and prevention of cancer, and an industrially useful method for manufacture of the same. Means: The quinazoline derivative represented by general formula (I) below: (in the formula, each of the symbols is the same as described in the specification) or a salt thereof, or a hydrate or solvate thereof, and a method for using the same to produce novel quinazoline derivatives.
    Type: Application
    Filed: November 26, 2004
    Publication date: November 22, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Hiroshi Iwamura, Takashi Naka
  • Morpholine Compound
    Publication number: 20070265257
    Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.
    Type: Application
    Filed: September 8, 2005
    Publication date: November 15, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Yoshihito Tanaka, Shuzo Takeda, Hidemitsu Higashi, Mamoru Matsuura, Fujio Kobayashi, Maiko Hamada, Minoru Tanaka
  • Quinazoline derivatives
    Patent number: 7294629
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: November 13, 2007
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Yasunori Kitano, Eiji Kawahara, Tsuyoshi Suzuki, Daisuke Abe, Masahiro Nakajou, Naoko Ueda
  • Substituted 8?-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8?-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives
    Patent number: 7294632
    Abstract: The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: November 13, 2007
    Assignees: Sanofi-Aventis, Mitsubishi Pharma Corporation
    Inventors: Pascal George, Alistair Lochead, Mourad Saady, Franck Slowinski, Philippe Yaiche
  • Substituted 8?-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-]pyrimidin-6-one derivatives
    Patent number: 7294631
    Abstract: The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, o, m, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: November 13, 2007
    Assignees: Sanofi-Aventis, Mitsubishi Pharma Corporation
    Inventors: Nathalie Chereze, Alistair Lochead, Mourad Saady, Franck Slowinski, Philippe Yaiche
  • THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF
    Publication number: 20070259880
    Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.
    Type: Application
    Filed: July 9, 2007
    Publication date: November 8, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Hiroshi SAKASHITA, Tomohiro YOSHIDA, Hiroshi KITAJIMA, Masahiro TAKEUCHI, Yoshihito TANAKA, Takuya YOSHIMURA, Fumihiko AKAHOSHI, Yoshiharu HAYASHI
  • Liposome
    Publication number: 20070248541
    Abstract: According to the present invention, a liposome encapsulating a water-soluble substance in an internal cavity of the liposome and having a liposome particle size of 300 nm or less can be easily prepared.
    Type: Application
    Filed: November 29, 2004
    Publication date: October 25, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Toshiaki Tagawa, Manami Ueda
  • THERAPEUTIC AGENT FOR SCHIZOPHRENIA
    Publication number: 20070244147
    Abstract: Provision of a pharmaceutical agent useful for the treatment of schizophrenia. As a solving means, a therapeutic agent for schizophrenia containing a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, an enantiomer thereof, an acid addition salt thereof or a hydrate or solvate thereof as an active ingredient is provided.
    Type: Application
    Filed: June 25, 2007
    Publication date: October 18, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Tomoko BESSHO, Ken TAKASHINA
  • Therapeutic Agent for Nonviral Hepatitis
    Publication number: 20070232614
    Abstract: The present invention provides a therapeutic drug for non-viral hepatitis, which contains a piperazine compound represented by the following formula (I) or pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: April 27, 2005
    Publication date: October 4, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Tetsuko Fukuda, Akira Mogami, Masao Hisadome, Kunitomo Adachi, Hirotsugu Komatsu
  • HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
    Publication number: 20070225300
    Abstract: The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3? or GSK3? and cdk5/p25, such as Alzheimer disease.
    Type: Application
    Filed: May 16, 2007
    Publication date: September 27, 2007
    Applicants: SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATION
    Inventors: Alistair LOCHEAD, Alain NEDELEC, Mourad SAADY, Philippe YAICHE
  • Insulin Resistance-Improving Agent
    Publication number: 20070212325
    Abstract: A medicament comprising a pharmaceutically acceptable anion exchange resin as an active ingredient is provided which exhibits an insulin resistance-improving action regardless of volume of meal or glucose absorption from the gastrointestinal tract.
    Type: Application
    Filed: March 25, 2005
    Publication date: September 13, 2007
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Kazuo Suzuki, Shigekazu Nakajima, Kanami Sugimoto
  • Method Of Assaying Substance Capable Of Changing Mitochondrial Membrane Potential
    Publication number: 20070202486
    Abstract: The present invention aims to provide a convenient and high precision evaluation method of a pharmaceutical agent that changes the mitochondrial membrane potential, using a mitochondrial membrane potential of a cultured cell as an index. The present invention provides a method for evaluating the ability of a test substance to change the mitochondrial membrane potential by using, as an index, the change in the mitochondrial membrane potential, which is produced by the addition of an ion permeability regulator on a cellular membrane to a cell culture medium, wherein the change is measured as variation in the fluorescent intensity of a fluorescent dye.
    Type: Application
    Filed: May 18, 2005
    Publication date: August 30, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Asami Umeda, Sumiko Nagaki
  • Use of Substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] Pyrimidin-4-one Derivatives as Therapeutic Agents
    Publication number: 20070191384
    Abstract: The invention relates to use of a substituted-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as described herein for treating a variety of disease states. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of GSK3?, such as Pick's disease.
    Type: Application
    Filed: April 4, 2007
    Publication date: August 16, 2007
    Applicants: SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATION
    Inventors: Alistair LOCHEAD, Mourad SAADY, Franck SLOWINSKI, Philippe YAICHE
  • Indazole compound and pharmaceutical use thereof
    Publication number: 20070173537
    Abstract: The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
    Type: Application
    Filed: February 10, 2005
    Publication date: July 26, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Akihiro Takemiya, Masahiro Nakajo, Hisae Oshima, Tomotaka Yanagi, Mami Mochizuki, Hideo Nakamura
  • 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives.
    Patent number: 7247638
    Abstract: The invention relates to substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer's disease.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: July 24, 2007
    Assignees: Sanofi-Aventis, Mitsubishi Pharma Corporation
    Inventors: Alistair Lochead, Mourad Saady, Franck Slowinski, Philippe Yaiche
  • USE OF SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES AS THERAPEUTIC AGENTS
    Publication number: 20070167461
    Abstract: The invention relates to an use of pyrimidone derivative represented by formula (I) or a salt thereof: wherein m, n, p, X, Y, R1, R2, R3, R4 and R5 are as defined herein for treating a variety of disease states. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3? or GSK3? and cdk5/p25, such as Alzheimer's disease.
    Type: Application
    Filed: April 5, 2007
    Publication date: July 19, 2007
    Applicants: SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATION
    Inventors: Thierry GALLET, Patrick LARDENOIS, Alistair LOCHEAD, Severine MARGUERIE, Alain NEDELEC, Mourad SAADY, Franck SLOWINSKI, Philippe YAICHE